AFMD Affimed N.V. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

AFMD [NASD]

Affimed N.V.

Healthcare | Biotechnology | Germany

statements

Index	-	P/E	-	EPS (ttm)	-0.75	Insider Own	7.50%	Shs Outstand	76.25M	Perf Week	-8.99%
Market Cap	286.48M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	0.00%	Shs Float	60.77M	Perf Month	-24.73%
Income	-50.50M	PEG	-	EPS next Q	-0.16	Inst Own	48.90%	Short Float	7.97%	Perf Quarter	73.74%
Sales	18.00M	P/S	15.92	EPS this Y	-56.50%	Inst Trans	1.42%	Short Ratio	2.93	Perf Half Y	33.85%
Book/sh	0.49	P/B	7.02	EPS next Y	33.30%	ROA	-43.10%	Target Price	-	Perf Year	21.99%
Cash/sh	1.26	P/C	2.73	EPS next 5Y	-	ROE	-136.10%	52W Range	1.42 - 4.91	Perf YTD	25.55%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-77.40%	52W High	-29.94%	Beta	2.55
Dividend %	-	Quick Ratio	2.60	Sales past 5Y	44.60%	Gross Margin	-	52W Low	142.25%	ATR	0.29
Employees	128	Current Ratio	2.60	Sales Q/Q	-55.30%	Oper. Margin	-	RSI (14)	40.04	Volatility	9.23% 7.06%
Optionable	Yes	Debt/Eq	0.08	EPS Q/Q	-466.40%	Profit Margin	-	Rel Volume	0.40	Prev Close	3.35
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Aug 11 BMO	Payout	-	Avg Volume	1.65M	Price	3.44
Recom	1.60	SMA20	-12.01%	SMA50	-13.07%	SMA200	22.13%	Volume	664,345	Change	2.69%

Mar-28-19

Initiated

SVB Leerink

Outperform

Aug-28-18

Upgrade

Jefferies

Hold → Buy

Jul-14-17

Initiated

SunTrust

Buy

Aug-12-16

Downgrade

Leerink Partners

Outperform → Mkt Perform

May-19-16

Downgrade

Leerink Partners

Outperform → Mkt Perform

Dec-10-15

Initiated

Laidlaw

Buy

$15

Dec-04-15

Initiated

Wells Fargo

Outperform

Sep-09-15

Initiated

Jefferies

Hold

Aug-06-15

Reiterated

Oppenheimer

Outperform

$14 → $19

Jun-22-15

Reiterated

Jefferies

Buy

$12 → $16

Aug-11-20 07:31PM	Affimed N.V. (AFMD) Q2 2020 Earnings Call Transcript Motley Fool -9.87%
07:55AM	Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:29AM	Affimed: Q2 Earnings Insights Benzinga
06:30AM	Affimed Reports Second Quarter 2020 Financial Results and Operational Progress GlobeNewswire
Aug-10-20 10:57AM	Earnings Outlook For Affimed Benzinga
Aug-05-20 06:30AM	Affimed Announces Two New Appointments to Its Supervisory Board GlobeNewswire
Aug-04-20 06:30AM	Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020 GlobeNewswire
Jul-31-20 08:23AM	Introducing Affimed (NASDAQ:AFMD), A Stock That Climbed 76% In The Last Three Years Simply Wall St.
Jul-29-20 12:33PM	Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -5.03%
Jul-10-20 06:30AM	Affimed Announces Annual General Meeting of Shareholders GlobeNewswire
Jun-30-20 11:03AM	Will Affimed Continue to Surge Higher? Zacks
Jun-29-20 08:43AM	Implied Volatility Surging for Affimed (AFMD) Stock Options Zacks
Jun-28-20 05:57PM	Hedge Funds Have Never Been This Bullish On Affimed NV (AFMD) Insider Monkey
Jun-25-20 06:02AM	Affimed N.V. (NASDAQ:AFMD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates Simply Wall St. +13.20%
Jun-23-20 07:57AM	The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout Benzinga
07:04AM	Affimed: Q1 Earnings Insights Benzinga
06:30AM	Affimed Reports First Quarter 2020 Financial Results and Operational Progress GlobeNewswire
06:30AM	Affimed NV to Host Earnings Call ACCESSWIRE
Jun-22-20 09:20AM	Affimed Announces Presentation of Data on Genentechs RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimeds ROCK® Platform, at AACR Virtual Annual Meeting II GlobeNewswire +13.66%
Jun-18-20 08:34AM	The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions Benzinga
Jun-17-20 06:30AM	Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers GlobeNewswire
Jun-16-20 09:47AM	Affimed (AFMD) Catches Eye: Stock Jumps 7.2% Zacks +8.23%
06:30AM	Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-12-20 02:23AM	Edited Transcript of AFMD earnings conference call or presentation 28-Apr-20 12:30pm GMT Thomson Reuters StreetEvents
Jun-11-20 06:30AM	Affimed Announces Appointment of Angus Smith as Chief Financial Officer GlobeNewswire -7.41%
May-29-20 08:05AM	Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting GlobeNewswire +5.45%
May-28-20 05:00AM	Affimed to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-15-20 05:00AM	Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II GlobeNewswire +19.19%
May-03-20 08:12AM	Downgrade: Here's How Analysts See Affimed N.V. (NASDAQ:AFMD) Performing In The Near Term Simply Wall St.
May-01-20 08:07AM	Earnings Update: Affimed N.V. (NASDAQ:AFMD) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St. -7.31%
Apr-29-20 12:00PM	All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to Buy Zacks
Apr-28-20 06:31PM	Affimed N.V. (AFMD) Q4 2019 Earnings Call Transcript Motley Fool
08:30AM	Affimed: Q4 Earnings Insights Benzinga
06:35AM	Affimed Reports 2019 Financial Results and Recent Operational Progress GlobeNewswire
Apr-16-20 07:30AM	Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers GlobeNewswire
Apr-02-20 07:57AM	The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation Benzinga
06:30AM	Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020 GlobeNewswire
Apr-01-20 04:01PM	Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma GlobeNewswire
Mar-26-20 07:30AM	Affimed Announces Participation at Upcoming Virtual Investor Conferences GlobeNewswire
Mar-24-20 04:00PM	Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies ACCESSWIRE
Mar-17-20 07:30AM	Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer GlobeNewswire +15.97%
Feb-19-20 07:30AM	Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference GlobeNewswire
Feb-03-20 07:30AM	Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer GlobeNewswire
Jan-10-20 06:30AM	Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer GlobeNewswire
Jan-07-20 03:23PM	Edited Transcript of AFMD earnings conference call or presentation 19-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Dec-17-19 07:30AM	Affimed Announces Addition to NASDAQ Biotechnology Index GlobeNewswire +6.95%
Dec-14-19 08:40PM	Is Affimed NV (AFMD) Going to Burn These Hedge Funds? Insider Monkey
Nov-27-19 08:08AM	New Strong Sell Stocks for November 27th Zacks
Nov-23-19 06:54AM	Affimed N.V. Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St.
Nov-19-19 08:45AM	Affimed N.V. (AFMD) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:30AM	Affimed Reports Third Quarter 2019 Financial Results and Recent Operational Progress GlobeNewswire
Nov-17-19 08:42AM	The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down Benzinga
Nov-14-19 06:30AM	Affimed to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire
06:30AM	Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019 GlobeNewswire
Nov-13-19 04:10PM	Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -7.14%
Nov-08-19 08:14AM	The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Benzinga -11.07%
06:30AM	Affimed Announces Pricing of Public Offering of Common Shares GlobeNewswire
Nov-07-19 04:11PM	Affimed Announces Proposed Public Offering of Common Shares GlobeNewswire
04:01PM	Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech GlobeNewswire
04:01PM	Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers GlobeNewswire
Oct-30-19 10:33AM	Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-19-19 08:23AM	Imagine Owning Affimed (NASDAQ:AFMD) And Wondering If The 35% Share Price Slide Is Justified Simply Wall St.
Oct-15-19 06:30AM	Affimed Reports Progress on Key Clinical Development Programs GlobeNewswire +9.74%
Sep-09-19 05:57PM	Edited Transcript of AFMD earnings conference call or presentation 7-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Sep-04-19 11:52AM	Is Affimed (NASDAQ:AFMD) Using Debt Sensibly? Simply Wall St.
Aug-28-19 05:00AM	Affimed to Participate in Investor Conferences in September GlobeNewswire
Aug-09-19 07:45PM	Affimed N.V. (AFMD) Q2 2019 Earnings Call Transcript Motley Fool +6.14%
Aug-07-19 09:05AM	Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:30AM	Affimed Reports Second Quarter 2019 Financial and Operational Results GlobeNewswire
Aug-06-19 02:16PM	Earnings Outlook For Affimed Benzinga
Jul-31-19 05:00AM	Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019 GlobeNewswire
Jul-18-19 01:03PM	Is Affimed N.V.'s (NASDAQ:AFMD) CEO Salary Justified? Simply Wall St.
Jul-02-19 09:00AM	All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to Buy Zacks
Jul-01-19 05:00AM	Affimed Added to the Russell 2000®, 3000® and Microcap Indexes GlobeNewswire
Jun-24-19 05:00AM	Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019 GlobeNewswire -14.66%
Jun-15-19 12:38PM	The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs Benzinga
Jun-12-19 07:55AM	Edited Transcript of AFMD earnings conference call or presentation 22-May-19 12:30pm GMT Thomson Reuters StreetEvents
05:30AM	Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland GlobeNewswire
Jun-04-19 04:01PM	Affimed Announces Annual General Meeting of Shareholders GlobeNewswire
Jun-03-19 05:00AM	Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagens Patented Mammalian Expression Technology GlobeNewswire
May-29-19 05:00AM	Affimed to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-23-19 02:25PM	Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1 Zacks
May-22-19 03:23PM	Affimed N.V. (AFMD) Q1 2019 Earnings Call Transcript Motley Fool -6.93%
08:45AM	Affirmed Therapeutics (AFMD) Beats Q1 Earnings and Revenue Estimates Zacks
07:58AM	Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10% MarketWatch
07:30AM	Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operational Progress GlobeNewswire
May-21-19 02:16PM	Affimed Q1 Earnings Preview Benzinga
May-16-19 05:00AM	Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019 GlobeNewswire
May-14-19 10:30AM	Affirmed Therapeutics (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
May-13-19 09:17AM	What's in Store for Affimed (AFMD) This Earnings Season? Zacks
Apr-30-19 09:00AM	Affirmed Therapeutics (AFMD) Moves to Buy: Rationale Behind the Upgrade Zacks
Apr-27-19 09:16AM	If You Had Bought Affimed (NASDAQ:AFMD) Shares A Year Ago You'd Have Made 62% Simply Wall St.
Apr-17-19 04:05PM	Affimed Provides Regulatory Update on AFM11 Clinical Program GlobeNewswire
Apr-09-19 08:48AM	Implied Volatility Surging for Affimed (AFMD) Stock Options Zacks
Apr-01-19 02:35PM	Edited Transcript of AFMD earnings conference call or presentation 27-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
08:00AM	Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting GlobeNewswire
Mar-27-19 01:49PM	Affimed N.V. (AFMD) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:30AM	Affimed Reports 2018 Financial Results and Operational Progress GlobeNewswire
Mar-20-19 05:00AM	Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019 GlobeNewswire
Mar-19-19 07:40AM	The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed Benzinga +6.89%

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience